From Nasdaq, Inc.:

Castle Biosciences Inc. (CSTL) is on track to generate over $210 million in revenue for fiscal year 2023, surpassing the minimum guidance of $200 million. The company delivered 20,284 total test reports in the fourth quarter of 2023, up from 12,644 in the same period of 2022. Total test reports for 2023 reached 70,429, a 59% increase from the previous year. Year-end 2023 cash and cash equivalents are projected to be approximately $99 million, with an additional $144 million in short-term investments.



Read more: Castle Biosciences Expects FY23 Revenue To Exceed $210 Mln, Surpassing Previous Outlook